<- Go Home
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF).
Market Cap
$103.7B
Volume
1.2M
Cash and Equivalents
$5.2B
EBITDA
$4.4B
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$5.7B
Profit Margin
53.59%
52 Week High
$519.88
52 Week Low
$377.85
Dividend
N/A
Price / Book Value
6.64
Price / Earnings
-216.13
Price / Tangible Book Value
7.57
Enterprise Value
$94.2B
Enterprise Value / EBITDA
20.93
Operating Income
$4.2B
Return on Equity
-2.99%
Return on Assets
12.05
Cash and Short Term Investments
$6.5B
Debt
$1.8B
Equity
$15.6B
Revenue
$10.6B
Unlevered FCF
$3.1B
Sector
Biotechnology
Category
N/A
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick Premium